10x Genomics (TXG) Liabilities and Shareholders Equity (2018 - 2026)

10x Genomics has disclosed Liabilities and Shareholders Equity across 9 years of filings, most recently posting $1.0 billion for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $1.0 billion, up 12.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.1 billion (up 10.16% YoY), and the FY2025 annual result was $1.0 billion, up 13.36% from the prior year.
• Liabilities and Shareholders Equity came in at $1.0 billion for Q1 2026 at 10x Genomics, down from $1.0 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.0 billion in Q4 2025 to a low of $903.4 million in Q1 2025.
• The 5-year median for Liabilities and Shareholders Equity is $989.6 million (2023), against an average of $977.9 million.
• Across the five-year window, Liabilities and Shareholders Equity fell 8.99% in 2024 and advanced 13.36% in 2025, its largest moves.
• 10x Genomics' Liabilities and Shareholders Equity stood at $1.0 billion in 2022, then slipped by 6.2% to $965.1 million in 2023, then decreased by 4.82% to $918.6 million in 2024, then rose by 13.36% to $1.0 billion in 2025, then slipped by 2.46% to $1.0 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.0 billion (Q1 2026), $1.0 billion (Q4 2025), and $1.0 billion (Q3 2025), per Business Quant data.